Stock News

Marinus Pharmaceuticals, Inc. (MRNS) Reaches $5.07 After 7.00% Up Move; Applied Materials (AMAT)’s Sentiment Is 0.86

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Logo

The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a huge mover today! The stock increased 3.05% or $0.15 during the last trading session, reaching $5.07. About 314,219 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 130.72% since May 23, 2017 and is uptrending. It has outperformed by 119.17% the S&P500.The move comes after 7 months positive chart setup for the $205.44 million company. It was reported on May, 23 by We have $5.42 PT which if reached, will make NASDAQ:MRNS worth $14.38M more.

Applied Materials Inc (AMAT) investors sentiment decreased to 0.86 in Q4 2017. It’s down -0.20, from 1.06 in 2017Q3. The ratio worsened, as 362 institutional investors started new and increased equity positions, while 419 cut down and sold their stakes in Applied Materials Inc. The institutional investors in our database reported: 797.20 million shares, down from 811.15 million shares in 2017Q3. Also, the number of institutional investors holding Applied Materials Inc in top ten equity positions decreased from 43 to 26 for a decrease of 17. Sold All: 52 Reduced: 367 Increased: 249 New Position: 113.

Since December 15, 2017, it had 0 insider purchases, and 2 selling transactions for $10.05 million activity. 1.27M shares were sold by Bain Capital Life Sciences Investors – LLC, worth $10.02 million. $23,730 worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was sold by Smith Edward F.

Another recent and important Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news was published by which published an article titled: “Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology …” on May 11, 2018.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $205.44 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

Investors sentiment decreased to 2 in 2017 Q4. Its down 0.80, from 2.8 in 2017Q3. It fall, as 7 investors sold Marinus Pharmaceuticals, Inc. shares while 11 reduced holdings. 23 funds opened positions while 13 raised stakes. 20.53 million shares or 8.19% more from 18.97 million shares in 2017Q3 were reported. The Massachusetts-based State Street has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). 425,000 were reported by New Leaf Venture Ptnrs Ltd Liability Corporation. Eam Invsts Ltd Liability accumulated 303,755 shares. Perceptive Advsr stated it has 0.25% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Pacad has 7,000 shares. Manufacturers Life Insur Communications The owns 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 1,468 shares. Moreover, Iguana Health Mngmt Ltd Liability Corp has 0.53% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Wells Fargo Mn reported 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Gsa Cap Partners Llp reported 20,500 shares. Cormorant Asset Management Ltd Liability Com reported 0.43% stake. Proshare Advsrs Ltd holds 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 21,782 shares. Northern Tru stated it has 50,472 shares. Arrowmark Colorado Ltd has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Susquehanna Gp Llp reported 68,162 shares or 0% of all its holdings. Caxton Corp holds 0.18% or 18,643 shares.

Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Marinus Pharmaceuticals had 10 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Tuesday, June 14. The stock has “Buy” rating by Mizuho on Monday, March 19. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has “Outperform” rating given on Wednesday, August 5 by Oppenheimer. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) earned “Outperform” rating by Oppenheimer on Friday, October 30. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, December 17. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, March 8. The rating was initiated by Jefferies with “Buy” on Tuesday, November 17. On Tuesday, June 14 the stock rating was downgraded by Oppenheimer to “Perform”. Jefferies maintained it with “Buy” rating and $2.50 target in Tuesday, June 14 report. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has “Buy” rating given on Wednesday, August 10 by Jefferies.

Since January 1, 0001, it had 0 insider buys, and 4 insider sales for $10.41 million activity.

Marble Arch Investments Lp holds 7.96% of its portfolio in Applied Materials, Inc. for 2.02 million shares. Egerton Capital (Uk) Llp owns 15.49 million shares or 6.93% of their US portfolio. Moreover, Scge Management L.P. has 6.81% invested in the company for 850,000 shares. The New York-based Praesidium Investment Management Company Llc has invested 5.86% in the stock. Guinness Atkinson Asset Management Inc, a California-based fund reported 137,610 shares.

Ratings analysis reveals 50% of Applied Materials’s analysts are positive. Out of 4 Wall Street analysts rating Applied Materials, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $30.0 while the high is $42.0. The stock’s average target of $34.83 is -30.38% below today’s ($50.0299) share price. AMAT was included in 4 notes of analysts from August 19, 2016. The firm has “Neutral” rating by Goldman Sachs given on Monday, December 19. The stock of Applied Materials, Inc. (NASDAQ:AMAT) has “Outperform” rating given on Friday, August 19 by Cowen & Co. RBC Capital Markets maintained it with “Sector Perform” rating and $30.0 target in Friday, August 19 report. The firm earned “Buy” rating on Monday, February 13 by Stifel Nicolaus.

The stock decreased 0.04% or $0.0201 during the last trading session, reaching $50.0299. About 9.06 million shares traded. Applied Materials, Inc. (AMAT) has risen 42.67% since May 23, 2017 and is uptrending. It has outperformed by 31.12% the S&P500.

Applied Materials, Inc. (NASDAQ:AMAT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *